K36 emerges with $30M to bankroll multiple myeloma drug in-licensed from Novartisnews2021-12-09T13:31:44+00:00December 9th, 2021|FierceBiotech|
Totus tots up $40M in series A funding to go after competitive cancer spacenews2021-12-09T13:15:02+00:00December 9th, 2021|FierceBiotech|
ASH: Senti Bio’s gene circuit CAR-NK cell therapy enhances cancer killing and safety in leukemia modelsnews2021-12-09T12:40:39+00:00December 9th, 2021|FierceBiotech|
Novartis works on pan-coronavirus pill, eyes 2022 human testingnews2021-12-09T09:34:05+00:00December 9th, 2021|FierceBiotech|
Science, talent, money: Eir raises $138M VC fund to fill gap in Nordic life science scenenews2021-12-08T15:50:12+00:00December 8th, 2021|FierceBiotech|
Fresh from $316M raise, Sotio inks Merck deal for Keytruda combo trialnews2021-12-08T13:38:34+00:00December 8th, 2021|FierceBiotech|
Merck KGaA steps up VC activity with $677M investment, positioning M Ventures to keep pace with changing landscapenews2021-12-08T08:52:10+00:00December 8th, 2021|FierceBiotech|
J&J squares up to Big Pharma rivals with extra RSV vaccine datanews2021-12-07T13:01:18+00:00December 7th, 2021|FierceBiotech|
Merck pauses 2 more trials of backbone HIV drug over red flag, raising doubts about multi-pronged R&D strategynews2021-12-07T10:44:24+00:00December 7th, 2021|FierceBiotech|
Merck pauses 2 more trials of backbone HIV drug over red flag, raising doubts about multipronged R&D strategynews2021-12-07T10:44:24+00:00December 7th, 2021|FierceBiotech|
